| Essential otolaryngology: head and neck surgery: a board preparation and concise reference KJ Lee (No Title), 1987 | 486 | 1987 |
| Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer K Sanchez, I Kim, B Chun, J Pucilowska, WL Redmond, WJ Urba, ... Breast Cancer Research 23, 1-15, 2021 | 40 | 2021 |
| Immunotherapy in breast cancer: an overview of modern checkpoint blockade strategies and vaccines K Sanchez, D Page, HL McArthur Current problems in cancer 40 (2-4), 151-162, 2016 | 32 | 2016 |
| Immunotherapy in triple-negative breast cancer: present and future I Kim, K Sanchez, HL McArthur, D Page Current Breast Cancer Reports 11, 259-271, 2019 | 28 | 2019 |
| A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy I Kim, V Rajamanickam, B Bernard, B Chun, Z Sun, WL Redmond, ... Frontiers in Oncology 11, 635237, 2021 | 22 | 2021 |
| Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC). DB Page, B Chun, J Pucilowska, I Kim, K Sanchez, WL Redmond, Z Sun, ... Journal of Clinical Oncology 37 (15_suppl), 1015-1015, 2019 | 21 | 2019 |
| Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC). DB Page, IK Kim, K Sanchez, N Moxon, SL Mellinger, AK Conlin, ... Journal of Clinical Oncology 36 (15_suppl), 1033-1033, 2018 | 15 | 2018 |
| Immunotherapy toxicities K Sanchez, DB Page, W Urba Surgical Oncology Clinics 28 (3), 387-401, 2019 | 14 | 2019 |
| Elacestrant and the promise of oral SERDs KG Sanchez, JR Nangia, R Schiff, MF Rimawi Journal of Clinical Oncology 40 (28), 3227-3229, 2022 | 12 | 2022 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| A phase Ib study of preoperative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early-stage breast cancer DB Page, J Pucilowska, KG Sanchez, VK Conrad, AK Conlin, AK Acheson, ... Clinical Cancer Research 26 (7), 1595-1605, 2020 | 9 | 2020 |
| Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations … DB Page, J Pucilowska, L Bennetts, I Kim, K Sanchez, M Martel, A Conlin, ... Cancer Research 79 (4_Supplement), P2-09-03-P2-09-03, 2019 | 7 | 2019 |
| A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer J Veeraraghavan, C Gutierrez, C De Angelis, R Davis, T Wang, T Pascual, ... Clinical Cancer Research 29 (16), 3101-3109, 2023 | 3 | 2023 |
| Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC … K Sanchez, I Kim, SC Chang, M Martel, Y Wu, B Bernard, J Pucilowska, ... CANCER RESEARCH 80 (4), 2020 | 2 | 2020 |
| Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline … DB Page, J Pucilowska, L Bennetts, I Kim, K Sanchez, M Martel, A Conlin, ... CANCER RESEARCH 79 (4), 2019 | 2 | 2019 |
| Abstract OT1-18-03: the neoIRX trial: locoregional cytokine therapy to promote immunologic priming and enhanced response to neoadjuvant pembrolizumab plus chemotherapy in … K Sanchez, A Conlin, P Peddi, S Stanton, J Ruzich, K Perlewitz, Y Wu, ... Cancer Research 82 (4_Supplement), OT1-18-03-OT1-18-03, 2022 | 1 | 2022 |
| Immunotherapy for Solid Malignancies TM Pawlik Surgical Oncology Clinics of North America 28 (3), xiii-xiv, 2019 | 1 | 2019 |
| Updated efficacy of first or second-line pembrolizumab plus in metastatic triple negative breast cancer and correlations with baseline lymphocyte and naïve CD4+ T-cell count D Page, J Pucilowska, L Bennetts, I Kim, K Sanchez, M Martel, A Conlin, ... | 1 | 2018 |
| Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy+/-Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial H McArthur, JHS Leal, I Chan, N Unni, S Shiao, J Gruber, S Syed, ... Cancer Research 84 (9_Supplement), PO5-19-08-PO5-19-08, 2024 | | 2024 |
| A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer DB Page, J Pucilowska, B Chun, I Kim, K Sanchez, N Moxon, S Mellinger, ... NPJ Breast Cancer 9 (1), 53, 2023 | | 2023 |
